A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Public ClinicalTrials.gov record NCT01113957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Clinical Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects With Recurrent High Grade Serous Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the objective response rate of ABT-888 when given in combination with temozolomide versus pegylated liposomal doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian cancer.
Study identification
- NCT ID
- NCT01113957
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- May 31, 2013
- Completion
- May 31, 2013
- Last update posted
- Jun 5, 2018
2010 – 2013
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 25028 | Duarte | California | 91010 | — |
| Site Reference ID/Investigator# 25024 | Encino | California | 91436 | — |
| Site Reference ID/Investigator# 25034 | Los Angeles | California | 90048 | — |
| Site Reference ID/Investigator# 25037 | Newport Beach | California | 92663 | — |
| Site Reference ID/Investigator# 25030 | Chicago | Illinois | 60637-1470 | — |
| Site Reference ID/Investigator# 27837 | Park Ridge | Illinois | 60068 | — |
| Site Reference ID/Investigator# 25039 | Peoria | Illinois | 61615-7828 | — |
| Site Reference ID/Investigator# 25038 | Albuquerque | New Mexico | 87131 | — |
| Site Reference ID/Investigator# 25023 | New York | New York | 10065 | — |
| Site Reference ID/Investigator# 25041 | Chapel Hill | North Carolina | 27599-7570 | — |
| Site Reference ID/Investigator# 25029 | Hilliard | Ohio | 43026 | — |
| Site Reference ID/Investigator# 25543 | Oklahoma City | Oklahoma | 73104 | — |
| Site Reference ID/Investigator# 25036 | Philadelphia | Pennsylvania | 19111 | — |
| Site Reference ID/Investigator# 25042 | Pittsburgh | Pennsylvania | 15213 | — |
| Site Reference ID/Investigator# 25027 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01113957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01113957 live on ClinicalTrials.gov.